SCHEMBL248035

SCHEMBL248035

[c]1cccc2c1ONC=C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30300660 0.68 MAPT (0.36)
SCHEMBL16341187 0.66 MAPT (0.37)
SCHEMBL8924 0.66 MAPT (0.37)
SCHEMBL3662203 0.66 MAPT (0.37)
SCHEMBL29804885 0.66 MAPT (0.37)
SCHEMBL5017973 0.65
SCHEMBL277103 0.64 CA1 (0.32)
SCHEMBL3201327 0.64 MAPT (0.36)
SCHEMBL7679297 0.64 MAPT (0.36)
Hydrochloric Acid SCHEMBL8699853 0.64 PARP1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024140933-A1 CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD AND USE THEREFOR 长春金赛药业有限责任公司 2024-07-04 WO disclosed
WO-2024140824-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-07-04 WO disclosed
CN-109843291-B Synthetic retinoids (cell modulation) 杜伦大学 2024-06-25 CN disclosed
CN-118108700-A Complement factor B inhibitor, pharmaceutical composition, preparation method and application thereof 诺华股份有限公司 2024-05-31 CN disclosed
WO-2024104452-A1 MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF 长春金赛药业有限责任公司 2024-05-23 WO disclosed
CN-117986235-A P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-05-07 CN disclosed
WO-2024067675-A1 FUSED RING KIF18A INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-04-04 WO disclosed
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-115403584-B 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
WO-2024061357-A1 HARRINGTONINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF 南开大学 2024-03-28 WO disclosed
US-20030225083-A1 Antidiabetic agents FAKHOURY STEPHEN A (US) 2003-12-04 US disclosed
US-20030225158-A1 Compounds that modulate PPAR activity and methods for their preparation WARNER-LAMBERT COMPANY 2003-12-04 US disclosed
US-20030220381-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY, LLC 2003-11-27 US disclosed
WO-2003084535-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-10-16 WO disclosed
WO-2003084916-A2 COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION WARNER-LAMBERT COMPANY LLC (US) 2003-10-16 WO disclosed
WO-2003082276-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 WO disclosed
US-20030171377-A1 Antidiabetic agents BIGGE CHRISTOPHER FRANKLIN (US) 2003-09-11 US disclosed
US-20030162787-A1 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade WARNER-LAMBERT COMPANY LLC 2003-08-28 US disclosed
WO-2003045912-A1 INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE WARNER-LAMBERT COMPANY LLC (US) 2003-06-05 WO disclosed
WO-2003018553-A1 ORAL ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-03-06 WO disclosed